Critical Survey: StageZero Life Sciences (OTCMKTS:GNWSF) & Evotec (OTCMKTS:EVTCY)
by Kim Johansen · The Markets DailyRisk & Volatility
StageZero Life Sciences has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Evotec has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.
Profitability
This table compares StageZero Life Sciences and Evotec’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| StageZero Life Sciences | -200.26% | N/A | -165.13% |
| Evotec | 20.85% | 16.02% | 7.81% |
Insider and Institutional Ownership
0.0% of StageZero Life Sciences shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares StageZero Life Sciences and Evotec”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| StageZero Life Sciences | $4.15 million | 0.02 | -$6.86 million | ($0.28) | -0.00 |
| Evotec | $572.16 million | 1.09 | $7.14 million | $0.41 | 4.59 |
Evotec has higher revenue and earnings than StageZero Life Sciences. StageZero Life Sciences is trading at a lower price-to-earnings ratio than Evotec, indicating that it is currently the more affordable of the two stocks.
Summary
Evotec beats StageZero Life Sciences on 9 of the 10 factors compared between the two stocks.
About StageZero Life Sciences
StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.
About Evotec
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.